Neurocrine Biosciences, Inc. NBIX

NAS: NBIX | ISIN: US64125C1099   1/07/2025
128,00 USD (+1,84%)
(+1,84%)   1/07/2025
Grafiek Neurocrine Biosciences, Inc. Grafiek Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc. in het nieuws

15 mei 2025 · Neurocrine Biosciences Presents Data on Improvements in Physiologic Glucocorticoid Dosing and Select Reproductive Hormones in Patients with Classic Congenital Adrenal Hyperplasia Taking CRENESSITY™ (crinecerfont) · Persbericht

14 mei 2025 · Neurocrine Biosciences Presents Findings Contributing to the Growing Body of Evidence on the Impact of High-Dose Glucocorticoids on Clinical Outcomes in Congenital Adrenal Hyperplasia · Persbericht

8 mei 2025 · Neurocrine Biosciences Announces New Results from Exploratory Analyses of the Phase 3 CAHtalyst™ Pediatric Study Demonstrating CRENESSITY™ Reduces Glucocorticoid Dosing While Maintaining or Improving Androstenedione Across Patient Subgroups · Persbericht

6 mei 2025 · Neurocrine Biosciences to Present at Upcoming Investor Conferences in May · Persbericht

6 mei 2025 · Neurocrine Biosciences and Carnie Wilson Team Up to Launch ConnectING with Carnie™ Awareness Campaign for People with Tardive Dyskinesia · Persbericht

5 mei 2025 · Neurocrine Biosciences Reports First Quarter 2025 Financial Results and Reaffirms 2025 Financial Guidance · Persbericht

5 mei 2025 · Neurocrine Biosciences Announces New Survey Revealing Need for Routine Screening and Earlier Diagnosis for People Living with Tardive Dyskinesia · Persbericht

30 april 2025 · Neurocrine Biosciences Initiates Phase 3 Registrational Program for NBI-1117568 as Potential Treatment for Adults with Schizophrenia · Persbericht

24 april 2025 · Neurocrine Biosciences Publishes Analysis Showing Long-Term Efficacy and a Consistent Safety Profile of INGREZZA® (valbenazine) Capsules in Older Adults with Tardive Dyskinesia in The Journal of Clinical Psychiatry · Persbericht

14 april 2025 · Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2025 Financial Results · Persbericht

Profiel Neurocrine Biosciences, Inc.

Biotechnologie
Gezondheidstechnologie
Productie
Productie van biologische producten

Website: www.neurocrine.com

Hoofdzetel: San Diego, California vlag Verenigde Staten

CEO: Kevin Gorman

Werknemers: 1.252

Mijn selecties